Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun A Azad

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry AnalysisDavid C Chen, James P Buteau, Nathan Papa, et al.
Nature Medicine|January 31, 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Future Oncology (London, England)|January 30, 2025
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 studyKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Nature Medicine|December 4, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Nature Medicine|May 27, 2025
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialEdmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer, et al.
The Lancet. Oncology|September 18, 2024
Sequential [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyArun A Azad, Mathias Bressel, Hsiang Tan, et al.
Translational Andrology and Urology|May 10, 2021
Whole blood <i>GRHL2</i> expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancerEdmond M Kwan, Heidi Fettke, Megan Crumbaker, et al.
European Urology|October 27, 2023
Administering [<sup>177</sup>Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 StudyRenu S Eapen, James P Buteau, Price Jackson, et al.
Cancers|October 13, 2021
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate CancerHui-Ming Lin, Nicole Yeung, Jordan F Hastings, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry AnalysisDavid C Chen, James P Buteau, Nathan Papa, et al.
Nature Medicine|January 31, 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Future Oncology (London, England)|January 30, 2025
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 studyKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Nature Medicine|December 4, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Nature Medicine|May 27, 2025
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialEdmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer, et al.
The Lancet. Oncology|September 18, 2024
Sequential [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyArun A Azad, Mathias Bressel, Hsiang Tan, et al.
Translational Andrology and Urology|May 10, 2021
Whole blood <i>GRHL2</i> expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancerEdmond M Kwan, Heidi Fettke, Megan Crumbaker, et al.
European Urology|October 27, 2023
Administering [<sup>177</sup>Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 StudyRenu S Eapen, James P Buteau, Price Jackson, et al.
Cancers|October 13, 2021
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate CancerHui-Ming Lin, Nicole Yeung, Jordan F Hastings, et al.
Pageof 14